| 摘要 |
Disclosed is an isolated monoclonal antibody which binds to human CD27, wherein the antibody comprises: (i) a heavy chain variable region CDR1 comprising GFTFSSYW, a heavy chain variable region CDR2 comprising IKQDGSEK, a heavy chain variable region CDR3 comprising VRELGMDWYFDL, a light chain variable region CDR1 comprising QSVDSY or QSVSSY, a light chain variable region CDR2 comprising DAS, and a light chain variable region CDR3 comprising QQRSNWPPT; (ii) a heavy chain variable region CDR1 comprising GFTFSSYD, a heavy chain variable region CDR2 comprising IWNDGSNK, a heavy chain variable region CDR3 comprising VGGTADLEHWDQ, a light chain variable region CDR1 comprising QGISSW, a light chain variable region CDR2 comprising AAS and a light chain variable region CDR3 comprising QQYNSYPLT; (iii) a heavy chain variable region CDR1 comprising GFTFNIYD a heavy chain variable region CDR2 comprising IWYDGSNQ, a heavy chain variable region CDR3 comprising ARGTHWGYFDY, a light chain variable region CDR1 comprising QGISSW, a light chain variable region CDR2 comprising AAS, and a light chain variable region CDR3 comprising QQYNSYPRT; (iv) a heavy chain variable region CDR1 comprising GFSFSSYG, a heavy chain variable region CDR2 comprising LWYDGSHK, a heavy chain variable region CDR3 comprising AREGLAVPGHWYFDL, a light chain variable region CDR1 comprising QGISSA, a light chain variable region CDR2 comprising DAS, and a light chain variable region CDR3 comprising QQFNTYPRT; (v) a heavy chain variable region CDR1 comprising GFTLSSHD, a heavy chain variable region CDR2 comprising IWNDGSNK, a heavy chain variable region CDR3 comprising VRGTADLEHWDQ, a light chain variable region CDR1 comprising QGISSW, a light chain variable region CDR2 comprising AAS, and a light chain variable region CDR3 comprising QQYNSYPLT; (vi) a heavy chain variable region CDR1 comprising GFTFSHYG, a heavy chain variable region CDR2 comprising IWYDGSNK, a heavy chain variable region CDR3 comprising ARDGWTTMVRGLNVFDI, a light chain variable region CDR1 comprising QDISSW or QGISSA, a light chain variable region CDR2 comprising AAS, and a light chain variable region CDR3 comprising QQYNSYPPT; or (vii) a heavy chain variable region CDR1 comprising GFTFSSYD, a heavy chain variable region CDR2 comprising IWYDGSNK, a heavy chain variable region CDR3 comprising ARGSGNWGFFDY, a light chain variable region CDR1 comprising QGISRW, a light chain variable region CDR2 comprising AAS, and a light chain variable region CDR3 comprising QQYNTYPRT. Also disclosed is the use of the above-described antibody for preparation of a medicament for treating cancer, a bacterial, fungal, viral or parasitic infectious disease; or graft rejection, allergy, and an autoimmune disease. |
